Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc. GRCL Peers
See (GRCL) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GRCL | $10.25 | +0.05% | 989.87M | -10.57 | -$0.97 | N/A |
| VRTX | $447.18 | +1.48% | 114.83B | -117.06 | -$3.82 | N/A |
| REGN | $614.79 | +3.06% | 65.26B | 15.63 | $39.34 | +0.29% |
| SGEN | $228.74 | -0.07% | 43.15B | -57.19 | -$4.00 | N/A |
| ALNY | $291.68 | -0.06% | 38.03B | -138.24 | -$2.11 | N/A |
| ARGX | $578.31 | +0.04% | 35.31B | 35.26 | $16.40 | N/A |
| BNTX | $101.72 | +4.01% | 24.45B | -28.57 | -$3.56 | N/A |
| BGNE | $184.71 | +0.49% | 20.21B | -22.55 | -$8.19 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.73B | N/A | N/A | N/A |
| RPRX | $33.09 | -3.39% | 18.63B | 13.51 | $2.45 | +2.62% |
Stock Comparison
GRCL vs VRTX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, VRTX has a market cap of 114.83B. Regarding current trading prices, GRCL is priced at $10.25, while VRTX trades at $447.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas VRTX's P/E ratio is -117.06. In terms of profitability, GRCL's ROE is -0.16%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, GRCL is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs REGN Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, REGN has a market cap of 65.26B. Regarding current trading prices, GRCL is priced at $10.25, while REGN trades at $614.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas REGN's P/E ratio is 15.63. In terms of profitability, GRCL's ROE is -0.16%, compared to REGN's ROE of +0.15%. Regarding short-term risk, GRCL is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs SGEN Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, SGEN has a market cap of 43.15B. Regarding current trading prices, GRCL is priced at $10.25, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas SGEN's P/E ratio is -57.19. In terms of profitability, GRCL's ROE is -0.16%, compared to SGEN's ROE of -0.17%. Regarding short-term risk, GRCL is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs ALNY Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ALNY has a market cap of 38.03B. Regarding current trading prices, GRCL is priced at $10.25, while ALNY trades at $291.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ALNY's P/E ratio is -138.24. In terms of profitability, GRCL's ROE is -0.16%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, GRCL is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs ARGX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ARGX has a market cap of 35.31B. Regarding current trading prices, GRCL is priced at $10.25, while ARGX trades at $578.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ARGX's P/E ratio is 35.26. In terms of profitability, GRCL's ROE is -0.16%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, GRCL is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs BNTX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, BNTX has a market cap of 24.45B. Regarding current trading prices, GRCL is priced at $10.25, while BNTX trades at $101.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas BNTX's P/E ratio is -28.57. In terms of profitability, GRCL's ROE is -0.16%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, GRCL is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs BGNE Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, BGNE has a market cap of 20.21B. Regarding current trading prices, GRCL is priced at $10.25, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas BGNE's P/E ratio is -22.55. In terms of profitability, GRCL's ROE is -0.16%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, GRCL is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs DNA-WT Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, DNA-WT has a market cap of 18.73B. Regarding current trading prices, GRCL is priced at $10.25, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, GRCL's ROE is -0.16%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, GRCL is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs RPRX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, RPRX has a market cap of 18.63B. Regarding current trading prices, GRCL is priced at $10.25, while RPRX trades at $33.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas RPRX's P/E ratio is 13.51. In terms of profitability, GRCL's ROE is -0.16%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, GRCL is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs SMMT Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, SMMT has a market cap of 17.99B. Regarding current trading prices, GRCL is priced at $10.25, while SMMT trades at $24.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas SMMT's P/E ratio is -71.74. In terms of profitability, GRCL's ROE is -0.16%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, GRCL is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs UTHR Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, UTHR has a market cap of 13.96B. Regarding current trading prices, GRCL is priced at $10.25, while UTHR trades at $309.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas UTHR's P/E ratio is 12.33. In terms of profitability, GRCL's ROE is -0.16%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, GRCL is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs INCY Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, INCY has a market cap of 12.64B. Regarding current trading prices, GRCL is priced at $10.25, while INCY trades at $65.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas INCY's P/E ratio is 326.50. In terms of profitability, GRCL's ROE is -0.16%, compared to INCY's ROE of +0.01%. Regarding short-term risk, GRCL is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs GMAB Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, GMAB has a market cap of 12.60B. Regarding current trading prices, GRCL is priced at $10.25, while GMAB trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas GMAB's P/E ratio is 11.96. In terms of profitability, GRCL's ROE is -0.16%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, GRCL is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs KRTX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, KRTX has a market cap of 12.60B. Regarding current trading prices, GRCL is priced at $10.25, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas KRTX's P/E ratio is -28.09. In terms of profitability, GRCL's ROE is -0.16%, compared to KRTX's ROE of -0.25%. Regarding short-term risk, GRCL is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs EXEL Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, EXEL has a market cap of 12.10B. Regarding current trading prices, GRCL is priced at $10.25, while EXEL trades at $44.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas EXEL's P/E ratio is 20.26. In terms of profitability, GRCL's ROE is -0.16%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, GRCL is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs BMRN Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, BMRN has a market cap of 11.49B. Regarding current trading prices, GRCL is priced at $10.25, while BMRN trades at $59.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas BMRN's P/E ratio is 22.20. In terms of profitability, GRCL's ROE is -0.16%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, GRCL is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs MRNA Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, MRNA has a market cap of 10.82B. Regarding current trading prices, GRCL is priced at $10.25, while MRNA trades at $27.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas MRNA's P/E ratio is -3.21. In terms of profitability, GRCL's ROE is -0.16%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, GRCL is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs ASND Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ASND has a market cap of 9.75B. Regarding current trading prices, GRCL is priced at $10.25, while ASND trades at $161.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ASND's P/E ratio is -24.90. In terms of profitability, GRCL's ROE is -0.16%, compared to ASND's ROE of +1.91%. Regarding short-term risk, GRCL is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs RXDX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, RXDX has a market cap of 9.56B. Regarding current trading prices, GRCL is priced at $10.25, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas RXDX's P/E ratio is -56.47. In terms of profitability, GRCL's ROE is -0.16%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, GRCL is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs IMGN Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, IMGN has a market cap of 8.73B. Regarding current trading prices, GRCL is priced at $10.25, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas IMGN's P/E ratio is -111.55. In terms of profitability, GRCL's ROE is -0.16%, compared to IMGN's ROE of +0.05%. Regarding short-term risk, GRCL is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs CERE Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, CERE has a market cap of 8.19B. Regarding current trading prices, GRCL is priced at $10.25, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas CERE's P/E ratio is -16.47. In terms of profitability, GRCL's ROE is -0.16%, compared to CERE's ROE of -0.99%. Regarding short-term risk, GRCL is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs CORT Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, CORT has a market cap of 8.08B. Regarding current trading prices, GRCL is priced at $10.25, while CORT trades at $76.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas CORT's P/E ratio is 66.28. In terms of profitability, GRCL's ROE is -0.16%, compared to CORT's ROE of +0.20%. Regarding short-term risk, GRCL is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs ROIV Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ROIV has a market cap of 7.88B. Regarding current trading prices, GRCL is priced at $10.25, while ROIV trades at $11.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ROIV's P/E ratio is -11.04. In terms of profitability, GRCL's ROE is -0.16%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, GRCL is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs ROIVW Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ROIVW has a market cap of 7.83B. Regarding current trading prices, GRCL is priced at $10.25, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, GRCL's ROE is -0.16%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, GRCL is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs TECH Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, TECH has a market cap of 7.76B. Regarding current trading prices, GRCL is priced at $10.25, while TECH trades at $49.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas TECH's P/E ratio is 59.67. In terms of profitability, GRCL's ROE is -0.16%, compared to TECH's ROE of +0.06%. Regarding short-term risk, GRCL is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs RVMD Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, RVMD has a market cap of 7.54B. Regarding current trading prices, GRCL is priced at $10.25, while RVMD trades at $40.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas RVMD's P/E ratio is -10.09. In terms of profitability, GRCL's ROE is -0.16%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, GRCL is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs JAZZ Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, JAZZ has a market cap of 6.84B. Regarding current trading prices, GRCL is priced at $10.25, while JAZZ trades at $111.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas JAZZ's P/E ratio is 15.08. In terms of profitability, GRCL's ROE is -0.16%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, GRCL is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs BPMC Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, BPMC has a market cap of 6.65B. Regarding current trading prices, GRCL is priced at $10.25, while BPMC trades at $103.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas BPMC's P/E ratio is -41.04. In terms of profitability, GRCL's ROE is -0.16%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, GRCL is less volatile compared to BPMC. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs HALO Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, HALO has a market cap of 6.59B. Regarding current trading prices, GRCL is priced at $10.25, while HALO trades at $53.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas HALO's P/E ratio is 14.22. In terms of profitability, GRCL's ROE is -0.16%, compared to HALO's ROE of +1.22%. Regarding short-term risk, GRCL is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs RETA Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, RETA has a market cap of 6.57B. Regarding current trading prices, GRCL is priced at $10.25, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas RETA's P/E ratio is -66.29. In terms of profitability, GRCL's ROE is -0.16%, compared to RETA's ROE of +0.47%. Regarding short-term risk, GRCL is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs MDGL Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, MDGL has a market cap of 6.50B. Regarding current trading prices, GRCL is priced at $10.25, while MDGL trades at $292.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas MDGL's P/E ratio is -16.41. In terms of profitability, GRCL's ROE is -0.16%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, GRCL is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs BBIO Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, BBIO has a market cap of 6.40B. Regarding current trading prices, GRCL is priced at $10.25, while BBIO trades at $33.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas BBIO's P/E ratio is -9.47. In terms of profitability, GRCL's ROE is -0.16%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, GRCL is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs VRNA Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, VRNA has a market cap of 6.35B. Regarding current trading prices, GRCL is priced at $10.25, while VRNA trades at $74.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas VRNA's P/E ratio is -37.36. In terms of profitability, GRCL's ROE is -0.16%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, GRCL is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs TGTX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, TGTX has a market cap of 5.63B. Regarding current trading prices, GRCL is priced at $10.25, while TGTX trades at $35.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas TGTX's P/E ratio is 141.88. In terms of profitability, GRCL's ROE is -0.16%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, GRCL is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs ABCM Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ABCM has a market cap of 5.52B. Regarding current trading prices, GRCL is priced at $10.25, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, GRCL's ROE is -0.16%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, GRCL is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs ISEE Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ISEE has a market cap of 5.51B. Regarding current trading prices, GRCL is priced at $10.25, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ISEE's P/E ratio is -22.44. In terms of profitability, GRCL's ROE is -0.16%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, GRCL is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs TLX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, TLX has a market cap of 5.49B. Regarding current trading prices, GRCL is priced at $10.25, while TLX trades at $16.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas TLX's P/E ratio is 182.22. In terms of profitability, GRCL's ROE is -0.16%, compared to TLX's ROE of +0.14%. Regarding short-term risk, GRCL is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs IONS Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, IONS has a market cap of 5.49B. Regarding current trading prices, GRCL is priced at $10.25, while IONS trades at $34.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas IONS's P/E ratio is -11.53. In terms of profitability, GRCL's ROE is -0.16%, compared to IONS's ROE of -0.00%. Regarding short-term risk, GRCL is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs NUVL Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, NUVL has a market cap of 5.45B. Regarding current trading prices, GRCL is priced at $10.25, while NUVL trades at $75.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas NUVL's P/E ratio is -17.17. In terms of profitability, GRCL's ROE is -0.16%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, GRCL is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs AXSM Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, AXSM has a market cap of 5.33B. Regarding current trading prices, GRCL is priced at $10.25, while AXSM trades at $108.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas AXSM's P/E ratio is -18.78. In terms of profitability, GRCL's ROE is -0.16%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, GRCL is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs ALKS Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ALKS has a market cap of 5.22B. Regarding current trading prices, GRCL is priced at $10.25, while ALKS trades at $31.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ALKS's P/E ratio is 15.08. In terms of profitability, GRCL's ROE is -0.16%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, GRCL is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs ADMA Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ADMA has a market cap of 4.88B. Regarding current trading prices, GRCL is priced at $10.25, while ADMA trades at $20.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ADMA's P/E ratio is 24.33. In terms of profitability, GRCL's ROE is -0.16%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, GRCL is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs PCVX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, PCVX has a market cap of 4.72B. Regarding current trading prices, GRCL is priced at $10.25, while PCVX trades at $36.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas PCVX's P/E ratio is -9.17. In terms of profitability, GRCL's ROE is -0.16%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, GRCL is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs ALPN Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ALPN has a market cap of 4.46B. Regarding current trading prices, GRCL is priced at $10.25, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ALPN's P/E ratio is -101.52. In terms of profitability, GRCL's ROE is -0.16%, compared to ALPN's ROE of -0.15%. Regarding short-term risk, GRCL is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs OPT Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, OPT has a market cap of 4.20B. Regarding current trading prices, GRCL is priced at $10.25, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas OPT's P/E ratio is -1.52. In terms of profitability, GRCL's ROE is -0.16%, compared to OPT's ROE of +2.60%. Regarding short-term risk, GRCL is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs MRTX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, MRTX has a market cap of 4.12B. Regarding current trading prices, GRCL is priced at $10.25, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas MRTX's P/E ratio is -4.82. In terms of profitability, GRCL's ROE is -0.16%, compared to MRTX's ROE of -0.40%. Regarding short-term risk, GRCL is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs RYTM Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, RYTM has a market cap of 4.06B. Regarding current trading prices, GRCL is priced at $10.25, while RYTM trades at $63.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas RYTM's P/E ratio is -22.81. In terms of profitability, GRCL's ROE is -0.16%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, GRCL is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs SRPT Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, SRPT has a market cap of 3.93B. Regarding current trading prices, GRCL is priced at $10.25, while SRPT trades at $39.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas SRPT's P/E ratio is -15.15. In terms of profitability, GRCL's ROE is -0.16%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, GRCL is less volatile compared to SRPT. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs CYTK Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, CYTK has a market cap of 3.90B. Regarding current trading prices, GRCL is priced at $10.25, while CYTK trades at $32.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas CYTK's P/E ratio is -6.17. In terms of profitability, GRCL's ROE is -0.16%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, GRCL is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs RNA Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, RNA has a market cap of 3.81B. Regarding current trading prices, GRCL is priced at $10.25, while RNA trades at $31.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas RNA's P/E ratio is -10.55. In terms of profitability, GRCL's ROE is -0.16%, compared to RNA's ROE of -0.27%. Regarding short-term risk, GRCL is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs KRYS Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, KRYS has a market cap of 3.80B. Regarding current trading prices, GRCL is priced at $10.25, while KRYS trades at $131.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas KRYS's P/E ratio is 31.55. In terms of profitability, GRCL's ROE is -0.16%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, GRCL is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs AKRO Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, AKRO has a market cap of 3.79B. Regarding current trading prices, GRCL is priced at $10.25, while AKRO trades at $47.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas AKRO's P/E ratio is -12.69. In terms of profitability, GRCL's ROE is -0.16%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, GRCL is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs RYZB Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, RYZB has a market cap of 3.75B. Regarding current trading prices, GRCL is priced at $10.25, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas RYZB's P/E ratio is -57.86. In terms of profitability, GRCL's ROE is -0.16%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, GRCL is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs PTCT Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, PTCT has a market cap of 3.74B. Regarding current trading prices, GRCL is priced at $10.25, while PTCT trades at $47.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas PTCT's P/E ratio is 7.25. In terms of profitability, GRCL's ROE is -0.16%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, GRCL is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs CBAY Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, CBAY has a market cap of 3.73B. Regarding current trading prices, GRCL is priced at $10.25, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas CBAY's P/E ratio is -32.81. In terms of profitability, GRCL's ROE is -0.16%, compared to CBAY's ROE of -0.32%. Regarding short-term risk, GRCL is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs ACAD Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ACAD has a market cap of 3.63B. Regarding current trading prices, GRCL is priced at $10.25, while ACAD trades at $21.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ACAD's P/E ratio is 15.83. In terms of profitability, GRCL's ROE is -0.16%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, GRCL is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs RARE Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, RARE has a market cap of 3.53B. Regarding current trading prices, GRCL is priced at $10.25, while RARE trades at $37.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas RARE's P/E ratio is -6.41. In terms of profitability, GRCL's ROE is -0.16%, compared to RARE's ROE of -1.86%. Regarding short-term risk, GRCL is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs SWTX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, SWTX has a market cap of 3.49B. Regarding current trading prices, GRCL is priced at $10.25, while SWTX trades at $46.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas SWTX's P/E ratio is -13.58. In terms of profitability, GRCL's ROE is -0.16%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, GRCL is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs CRSP Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, CRSP has a market cap of 3.39B. Regarding current trading prices, GRCL is priced at $10.25, while CRSP trades at $39.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas CRSP's P/E ratio is -8.74. In terms of profitability, GRCL's ROE is -0.16%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, GRCL is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs ACLX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ACLX has a market cap of 3.34B. Regarding current trading prices, GRCL is priced at $10.25, while ACLX trades at $60.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ACLX's P/E ratio is -20.25. In terms of profitability, GRCL's ROE is -0.16%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, GRCL is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs VKTX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, VKTX has a market cap of 3.22B. Regarding current trading prices, GRCL is priced at $10.25, while VKTX trades at $28.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas VKTX's P/E ratio is -24.72. In terms of profitability, GRCL's ROE is -0.16%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, GRCL is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs SLNO Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, SLNO has a market cap of 3.21B. Regarding current trading prices, GRCL is priced at $10.25, while SLNO trades at $69.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas SLNO's P/E ratio is -15.97. In terms of profitability, GRCL's ROE is -0.16%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, GRCL is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs MTSR Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, MTSR has a market cap of 3.07B. Regarding current trading prices, GRCL is priced at $10.25, while MTSR trades at $29.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas MTSR's P/E ratio is -11.56. In terms of profitability, GRCL's ROE is -0.16%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, GRCL is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs MRUS Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, MRUS has a market cap of 3.05B. Regarding current trading prices, GRCL is priced at $10.25, while MRUS trades at $44.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas MRUS's P/E ratio is -10.58. In terms of profitability, GRCL's ROE is -0.16%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, GRCL is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs CPRX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, CPRX has a market cap of 3.01B. Regarding current trading prices, GRCL is priced at $10.25, while CPRX trades at $24.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas CPRX's P/E ratio is 15.72. In terms of profitability, GRCL's ROE is -0.16%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, GRCL is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs SRRK Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, SRRK has a market cap of 2.99B. Regarding current trading prices, GRCL is priced at $10.25, while SRRK trades at $31.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas SRRK's P/E ratio is -12.37. In terms of profitability, GRCL's ROE is -0.16%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, GRCL is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs CRNX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, CRNX has a market cap of 2.94B. Regarding current trading prices, GRCL is priced at $10.25, while CRNX trades at $31.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas CRNX's P/E ratio is -8.26. In terms of profitability, GRCL's ROE is -0.16%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, GRCL is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs PTGX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, PTGX has a market cap of 2.89B. Regarding current trading prices, GRCL is priced at $10.25, while PTGX trades at $46.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas PTGX's P/E ratio is 59.76. In terms of profitability, GRCL's ROE is -0.16%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, GRCL is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs MORF Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, MORF has a market cap of 2.86B. Regarding current trading prices, GRCL is priced at $10.25, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas MORF's P/E ratio is -14.88. In terms of profitability, GRCL's ROE is -0.16%, compared to MORF's ROE of -0.27%. Regarding short-term risk, GRCL is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs MOR Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, MOR has a market cap of 2.86B. Regarding current trading prices, GRCL is priced at $10.25, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas MOR's P/E ratio is -12.64. In terms of profitability, GRCL's ROE is -0.16%, compared to MOR's ROE of +7.43%. Regarding short-term risk, GRCL is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs LEGN Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, LEGN has a market cap of 2.77B. Regarding current trading prices, GRCL is priced at $10.25, while LEGN trades at $30.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas LEGN's P/E ratio is -25.48. In terms of profitability, GRCL's ROE is -0.16%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, GRCL is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs KDNY Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, KDNY has a market cap of 2.71B. Regarding current trading prices, GRCL is priced at $10.25, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas KDNY's P/E ratio is -12.47. In terms of profitability, GRCL's ROE is -0.16%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, GRCL is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs MYOV Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, MYOV has a market cap of 2.62B. Regarding current trading prices, GRCL is priced at $10.25, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas MYOV's P/E ratio is -14.05. In terms of profitability, GRCL's ROE is -0.16%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, GRCL is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs IBRX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, IBRX has a market cap of 2.56B. Regarding current trading prices, GRCL is priced at $10.25, while IBRX trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas IBRX's P/E ratio is -5.09. In terms of profitability, GRCL's ROE is -0.16%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, GRCL is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs MLTX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, MLTX has a market cap of 2.56B. Regarding current trading prices, GRCL is priced at $10.25, while MLTX trades at $40.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas MLTX's P/E ratio is -17.51. In terms of profitability, GRCL's ROE is -0.16%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, GRCL is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs IMVT Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, IMVT has a market cap of 2.55B. Regarding current trading prices, GRCL is priced at $10.25, while IMVT trades at $15.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas IMVT's P/E ratio is -5.73. In terms of profitability, GRCL's ROE is -0.16%, compared to IMVT's ROE of -0.78%. Regarding short-term risk, GRCL is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs XENE Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, XENE has a market cap of 2.41B. Regarding current trading prices, GRCL is priced at $10.25, while XENE trades at $31.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas XENE's P/E ratio is -9.76. In terms of profitability, GRCL's ROE is -0.16%, compared to XENE's ROE of -0.32%. Regarding short-term risk, GRCL is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs APGE Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, APGE has a market cap of 2.40B. Regarding current trading prices, GRCL is priced at $10.25, while APGE trades at $40.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas APGE's P/E ratio is -11.17. In terms of profitability, GRCL's ROE is -0.16%, compared to APGE's ROE of -0.19%. Regarding short-term risk, GRCL is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs PRVB Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, PRVB has a market cap of 2.38B. Regarding current trading prices, GRCL is priced at $10.25, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas PRVB's P/E ratio is -16.43. In terms of profitability, GRCL's ROE is -0.16%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, GRCL is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs LBPH Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, LBPH has a market cap of 2.34B. Regarding current trading prices, GRCL is priced at $10.25, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas LBPH's P/E ratio is -26.66. In terms of profitability, GRCL's ROE is -0.16%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, GRCL is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs APLS Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, APLS has a market cap of 2.33B. Regarding current trading prices, GRCL is priced at $10.25, while APLS trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas APLS's P/E ratio is -10.28. In terms of profitability, GRCL's ROE is -0.16%, compared to APLS's ROE of -1.00%. Regarding short-term risk, GRCL is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs DICE Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, DICE has a market cap of 2.27B. Regarding current trading prices, GRCL is priced at $10.25, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas DICE's P/E ratio is -21.91. In terms of profitability, GRCL's ROE is -0.16%, compared to DICE's ROE of +0.56%. Regarding short-term risk, GRCL is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for GRCL.
GRCL vs VCYT Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, VCYT has a market cap of 2.26B. Regarding current trading prices, GRCL is priced at $10.25, while VCYT trades at $28.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas VCYT's P/E ratio is 68.60. In terms of profitability, GRCL's ROE is -0.16%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, GRCL is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs ARWR Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, ARWR has a market cap of 2.25B. Regarding current trading prices, GRCL is priced at $10.25, while ARWR trades at $16.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas ARWR's P/E ratio is -13.14. In terms of profitability, GRCL's ROE is -0.16%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, GRCL is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs MIRM Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, MIRM has a market cap of 2.25B. Regarding current trading prices, GRCL is priced at $10.25, while MIRM trades at $45.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas MIRM's P/E ratio is -28.16. In terms of profitability, GRCL's ROE is -0.16%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, GRCL is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs VCEL Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, VCEL has a market cap of 2.19B. Regarding current trading prices, GRCL is priced at $10.25, while VCEL trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas VCEL's P/E ratio is 870.40. In terms of profitability, GRCL's ROE is -0.16%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, GRCL is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs NAMS Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, NAMS has a market cap of 2.17B. Regarding current trading prices, GRCL is priced at $10.25, while NAMS trades at $19.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas NAMS's P/E ratio is -10.52. In terms of profitability, GRCL's ROE is -0.16%, compared to NAMS's ROE of -0.26%. Regarding short-term risk, GRCL is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs BCRX Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, BCRX has a market cap of 2.16B. Regarding current trading prices, GRCL is priced at $10.25, while BCRX trades at $10.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas BCRX's P/E ratio is -39.73. In terms of profitability, GRCL's ROE is -0.16%, compared to BCRX's ROE of +0.15%. Regarding short-term risk, GRCL is less volatile compared to BCRX. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs CALT Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, CALT has a market cap of 2.15B. Regarding current trading prices, GRCL is priced at $10.25, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas CALT's P/E ratio is -22.73. In terms of profitability, GRCL's ROE is -0.16%, compared to CALT's ROE of -2.10%. Regarding short-term risk, GRCL is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs NAMSW Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, NAMSW has a market cap of 2.12B. Regarding current trading prices, GRCL is priced at $10.25, while NAMSW trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas NAMSW's P/E ratio is N/A. In terms of profitability, GRCL's ROE is -0.16%, compared to NAMSW's ROE of -0.26%. Regarding short-term risk, GRCL is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs BLTE Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, BLTE has a market cap of 2.11B. Regarding current trading prices, GRCL is priced at $10.25, while BLTE trades at $64.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas BLTE's P/E ratio is -47.65. In terms of profitability, GRCL's ROE is -0.16%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, GRCL is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs DNLI Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, DNLI has a market cap of 2.08B. Regarding current trading prices, GRCL is priced at $10.25, while DNLI trades at $14.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas DNLI's P/E ratio is -5.35. In terms of profitability, GRCL's ROE is -0.16%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, GRCL is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs KYMR Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, KYMR has a market cap of 2.05B. Regarding current trading prices, GRCL is priced at $10.25, while KYMR trades at $31.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas KYMR's P/E ratio is -10.11. In terms of profitability, GRCL's ROE is -0.16%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, GRCL is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs HRMY Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, HRMY has a market cap of 2.05B. Regarding current trading prices, GRCL is priced at $10.25, while HRMY trades at $35.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas HRMY's P/E ratio is 13.60. In terms of profitability, GRCL's ROE is -0.16%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, GRCL is less volatile compared to HRMY. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs FOLD Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, FOLD has a market cap of 2.03B. Regarding current trading prices, GRCL is priced at $10.25, while FOLD trades at $6.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas FOLD's P/E ratio is -73.22. In terms of profitability, GRCL's ROE is -0.16%, compared to FOLD's ROE of -0.17%. Regarding short-term risk, GRCL is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs CGON Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, CGON has a market cap of 2.02B. Regarding current trading prices, GRCL is priced at $10.25, while CGON trades at $26.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas CGON's P/E ratio is -17.71. In terms of profitability, GRCL's ROE is -0.16%, compared to CGON's ROE of -0.11%. Regarding short-term risk, GRCL is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs LGND Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, LGND has a market cap of 2.02B. Regarding current trading prices, GRCL is priced at $10.25, while LGND trades at $104.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas LGND's P/E ratio is -14.39. In terms of profitability, GRCL's ROE is -0.16%, compared to LGND's ROE of -0.16%. Regarding short-term risk, GRCL is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs AAPG Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, AAPG has a market cap of 2.00B. Regarding current trading prices, GRCL is priced at $10.25, while AAPG trades at $23.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas AAPG's P/E ratio is -31.08. In terms of profitability, GRCL's ROE is -0.16%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, GRCL is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.
GRCL vs KNSA Comparison
GRCL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRCL stands at 989.87M. In comparison, KNSA has a market cap of 1.95B. Regarding current trading prices, GRCL is priced at $10.25, while KNSA trades at $26.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRCL currently has a P/E ratio of -10.57, whereas KNSA's P/E ratio is -111.25. In terms of profitability, GRCL's ROE is -0.16%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, GRCL is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for GRCL.